^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ARHGAP

    i
    Other names: ARHGAP
    1m
    Young-Onset Gastric Cancer: Clinical and Genetic Perspectives. (PubMed, J Gastric Cancer)
    We emphasize opportunities to refine risk stratification, integrate hereditary cancer management, and adopt emerging tools, such as liquid biopsy, for early detection and disease monitoring. Ultimately, defining the biological foundations of YOGC may enable tailored interventions and improve prognosis in this increasingly relevant and understudied population.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18) • CDH1 (Cadherin 1) • RHOA (Ras homolog family member A) • EGF (Epidermal growth factor) • ARHGAP
    5ms
    Integrated analysis of ARHGAP6 potential function and prognostic value in acute myeloid leukemia. (PubMed, PLoS One)
    From cell lines-based functional assays to bioinformatic analysis, this study demonstrated that clinical potential of ARHGAP6 as a novel biomarker of AML.
    Journal
    |
    PDGFRB (Platelet Derived Growth Factor Receptor Beta) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase) • ARHGAP • HCK (HCK Proto-Oncogene)
    11ms
    Understanding the Role of Rho GTPase Activating Protein and Bone Marrow Kinase X: A Novel Target in Gastric Cancer Treatment. (PubMed, Asian Pac J Cancer Prev)
    The evidence supports the critical involvement of ARHGAP and BMX in GC, suggesting their potential as therapeutic targets. Further research is essential to clarify the mechanisms by which these proteins influence gastric cancer progression and to evaluate their viability as targets for new therapeutic strategies.
    Review • Journal
    |
    ARHGAP
    12ms
    ARHGAP12 and ARHGAP29 exert distinct regulatory effects on switching between two cell morphological states through GSK-3 activity. (PubMed, Cell Rep)
    In patients with glioblastoma (GBM), we identify a link between ARHGAP12 and ARHGAP29 co-expression and recurrence after treatment. Consequently, we propose that further investigation of how ARHGAPs regulate transitional morphological events to drive cancer dissemination is warranted.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH2 (Cadherin 2) • ARHGAP
    12ms
    Evaluating the pharmacokinetics of zolbetuximab in gastric adenocarcinoma. (PubMed, Expert Opin Drug Metab Toxicol)
    Examining how to improve upon outcomes will be of benefit. Additionally, there are GAC subsets who may also have benefit from zolbetuximab but need more close examination such as those with moderate CLDN18.2 expressed tumors, low CLDN18.2 expressed tumors, and CLD18-ARHGAP fusion patients.
    PK/PD data • Review • Journal
    |
    CLDN18 (Claudin 18) • ARHGAP
    |
    Vyloy (zolbetuximab-clzb)
    1year
    Chemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin's lymphoma via CCR7/ARHGAP18/IKBα signaling activation. (PubMed, J Immunother Cancer)
    Together, TIS promotes the stemness of B-NHL cells via CCR7/ARHGAP18/IKBα signaling activation and targeting CCR7/ARHGAP18 might overcome the chemoresistance of senescent B-NHL cells by inhibiting stemness acquisition and maintenance.
    Journal
    |
    RHOA (Ras homolog family member A) • CCR7 (Chemokine (C-C motif) receptor 7) • ARHGAP • CCL21 (C-C Motif Chemokine Ligand 21)
    |
    CCR7 overexpression • CCR7 expresion
    |
    doxorubicin hydrochloride
    over1year
    Detection of Novel Fusion Events in Gastric Carcinoma Involving the ARHGAP Gene Family (AMP 2024)
    Our study documents novel fusions in MSS gastric carcinoma involving the ARHGAP family. Patients with these tumors usually lack eligibility for targeted therapies, such as those directed against HER2 and involving immune checkpoint inhibition, and could ultimately benefit from new treatment avenues modulating RHOA activity as a result of ARHGAP fusions.
    Tumor mutational burden • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ARID1A (AT-rich interaction domain 1A) • CLDN18 (Claudin 18) • PBRM1 (Polybromo 1) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • KDM6A (Lysine Demethylase 6A) • RHOA (Ras homolog family member A) • SOX9 (SRY-Box Transcription Factor 9) • ELF3 (E74 Like ETS Transcription Factor 3) • ARHGAP • CDKN1B (Cyclin dependent kinase inhibitor 1B) • CTNND1 (Catenin Delta 1) • ARHGAP42 (Rho GTPase Activating Protein 42)
    |
    TMB-H • HER-2 amplification • PBRM1 mutation
    |
    MI Tumor Seek™
    over1year
    Upregulation of ARHGAP9 is correlated with poor prognosis and immune infiltration in clear cell renal cell carcinoma. (PubMed, Medicine (Baltimore))
    These findings demonstrate that upregulated ARHGAP9 indicates poor prognosis and immune infiltration in ccRCC. The current findings suggest that ARHGAP9 can be an effective biomarker and potential therapeutic strategy for ccRCC.
    Journal
    |
    ARHGAP
    over1year
    Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer. (PubMed, EMBO Mol Med)
    Furthermore, PI3K inhibition could effectively reverse Treg cells upregulation to enhance anti-tumor cytotoxicity of neoantigen-reactive T cells in vitro and reduce tumor growth in the xenograft gastric cancer model. Our study identified the CLDN18-ARHGAP fusion gene as a critical source of immunogenic neoepitopes, a key regulator of the tumor immune microenvironment, and immunotherapeutic applications specific to this oncogenic fusion.
    Journal
    |
    CLDN18 (Claudin 18) • ARHGAP
    over1year
    The expression and clinical significance of ARHGAP25 in osteosarcoma based on bioinformatics analysis. (PubMed, Sci Rep)
    In addition, ARHGAP25 is also associated with immune-related pathways in osteosarcoma. These findings suggest that ARHGAP25 is a valuable prognostic biomarker in osteosarcoma patients.
    Journal
    |
    ARHGAP
    over1year
    A novel ARHGAP family gene signature for survival prediction in glioma patients. (PubMed, J Cell Mol Med)
    DCA analysis and cellular studies confirmed the model's potential to improve clinical treatment outcomes for patients. A novel ARHGAP family gene signature reveals the prognosis of glioma.
    Journal • Tumor mutational burden • Gene Signature
    |
    TMB (Tumor Mutational Burden) • ARHGAP • ARHGAP30 (Rho GTPase Activating Protein 30)
    over1year
    High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC). (PubMed, J Immunother Cancer)
    This work highlights RPL13A and GNL3 as potential indicative biomarkers of resistance to PD-1 axis blockade that might help to improve precision immunotherapy strategies for lung cancer.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPAS1 (Endothelial PAS domain protein 1) • CD68 (CD68 Molecule) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • ARHGAP • RPL5 (Ribosomal Protein L5) • HSPD1 (Heat Shock Protein Family D (Hsp60) Member 1) • RPL13A (Ribosomal Protein L13a)